Holen Sie sich die Stockscreener-App
9.265
4.69%
0.415
Handel nachbörslich:
9.27
0.005
+0.05%
Schlusskurs vom Vortag:
$8.85
Offen:
$8.84
24-Stunden-Volumen:
8,680
Relative Volume:
0.07
Marktkapitalisierung:
$8.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.80M
KGV:
-7.7857
EPS:
-1.19
Netto-Cashflow:
$-25.19M
1W Leistung:
+7.80%
1M Leistung:
+46.97%
6M Leistung:
-10.05%
1J Leistung:
-26.48%
1-Tages-Spanne:
$8.72
$9.32
1-Wochen-Bereich:
$7.62
$9.32
52-Wochen-Spanne:
$5.00
$17.40
Sensei Biotherapeutics Inc Stock (SNSE) Company Profile
Firmenname
Sensei Biotherapeutics Inc
Sektor
Branche
Telefon
(240) 243-8000
Adresse
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Vergleichen Sie SNSE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
9.265 | 8.24M | 0 | -29.80M | -25.19M | -1.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sensei Biotherapeutics Inc Stock (SNSE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2021-07-01 | Herabstufung | Berenberg | Buy → Hold |
| 2021-06-29 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-03-01 | Eingeleitet | Berenberg | Buy |
| 2021-03-01 | Eingeleitet | Citigroup | Buy |
| 2021-03-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-01 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Sensei Biotherapeutics Inc Aktie (SNSE) Neueste Nachrichten
Sensei Biotherapeutics (SNSE) Trading Halted Amid Pending News | SNSE Stock News - GuruFocus
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split | - GuruFocus
Sensei Biotherapeutics to implement 1-for-20 reverse stock split - Investing.com Australia
Sensei Biotherapeutics to implement 1-for-20 reverse stock split By Investing.com - Investing.com Canada
Sensei Biotherapeutics announces reverse stock split By Investing.com - Investing.com Canada
Sensei Biotherapeutics to Implement 1-for-20 Reverse Stock Split - MarketScreener
Sensei Biotherapeutics Announces Reverse Stock Split - TipRanks
Sensei Biotherapeutics Sets 1-for-20 Reverse Stock Split - Nasdaq
Sensei Biotherapeutics announces reverse stock split - Investing.com
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split | SNSE Stock News - GuruFocus
Sensei Biotherapeutics (SNSE) Announces 1-for-20 Reverse Stock Split | SNSE Stock News - GuruFocus
Sensei Biotherapeutics Announces 1-For-20 Reverse Stock Split - marketscreener.com
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split - GlobeNewswire
Sensei Bio's 1:20 Reverse Split Slashes Outstanding Shares from 25M to 1.3MWhat Investors Must Know - Stock Titan
What is HC Wainwright’s Forecast for SNSE Q2 Earnings? - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Upgraded at HC Wainwright - Defense World
Sensei Biotherapeutics (SNSE) Receives a 'Buy' Rating from HC Wainwright | SNSE Stock News - GuruFocus
Sensei Biotherapeutics (SNSE) Receives Buy Rating from H.C. Wain - GuruFocus
Sensei Biotherapeutics (SNSE) Receives Buy Rating from H.C. Wainwright | SNSE Stock News - GuruFocus
H.C. Wainwright assumes Buy rating on Sensei Biotherapeutics stock By Investing.com - Investing.com Canada
VISTA Inhibitor Clinical Trials Market Insights and Drug Development Opportunities Report 2025-2028 Featuring Aurigene, Curis, Hummingbird Bioscience, Kineta, PharmAbcine, Sensei BiotherapeuticsResearchAndMarkets.com - FinancialContent
Sensei Biotherapeutics stockholders approve key proposals By Investing.com - Investing.com Nigeria
Sensei Biotherapeutics stockholders approve key proposals - Investing.com
Sensei Biotherapeutics Approves Reverse Stock Split - TipRanks
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Shares Sold by Renaissance Technologies LLC - Defense World
Sensei Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sensei (SNSE) Reports Encouraging Clinical Results in Recent Qua - GuruFocus
Sensei Biotherapeutics Reports Promising Q1 2025 Results - TipRanks
Sensei Biotherapeutics Reports First Quarter 2025 Financial Resu - GuruFocus
Sensei (SNSE) Reports Encouraging Clinical Results in Recent Quarter | SNSE Stock News - GuruFocus
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress - The Manila Times
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress | SNSE Stock News - GuruFocus
Sensei Bio's Cancer Drug Achieves Breakthrough: 3X Better Response in PD-L1 Resistant Patients - Stock Titan
Sensei Biotherapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
SEC Form DEF 14A filed by Sensei Biotherapeutics Inc. - Quantisnow
Penny Stocks To Add to Your WatchlistMarch 30th - MarketBeat
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - The Manila Times
Promising Penny Stocks To ResearchMarch 29th - MarketBeat
Best Penny Stocks To Follow NowMarch 28th - MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Sensei Biotherapeutics stock hits 52-week low at $0.34 By Investing.com - Investing.com South Africa
Sensei Biotherapeutics stock hits 52-week low at $0.34 - Investing.com
HC Wainwright Reiterates Buy Rating for Sensei Biotherapeutics (NASDAQ:SNSE) - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Price Target Raised to $4.00 at Oppenheimer - Armenian Reporter
Sensei Biotherapeutics Reports Promising 2024 Results - TipRanks
Sensei Biotherapeutics (SNSE) Reports Annual Loss and Decline in Cash Reserves - GuruFocus
Sensei stock holds Buy rating, $4 target from H.C. Wainwright By Investing.com - Investing.com Australia
Sensei Rockets on FY ’24 Results - Baystreet.ca
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors - Benzinga
Finanzdaten der Sensei Biotherapeutics Inc-Aktie (SNSE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):